Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

OBJECTIVE: To evaluate the efficacy and safety of ABT‐494, a selective JAK‐1 inhibitor, in patients with moderate‐to‐severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). METHODS: Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to r...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., Smolen, Josef S., Weinblatt, Michael E., Burmester, Gerd R., Meerwein, Sebastian, Camp, Heidi S., Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132065/
https://www.ncbi.nlm.nih.gov/pubmed/27390150
http://dx.doi.org/10.1002/art.39808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132065/
https://www.ncbi.nlm.nih.gov/pubmed/27390150
http://dx.doi.org/10.1002/art.39808

Ejemplares similares